Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Theratechnologies closes US$57.7 million bought deal financing

Fasken
Reading Time 1 minute read
Client

Theratechnologies

On February 27, 2007, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 6,875,000 common shares at a price of $8.40 per share for gross proceeds of $57,750,000. The offering was made through a syndicate of underwriters led by BMO Capital Markets, including Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. The offering included the 625,000 additional shares issued pursuant to the over-allotment option, which was exercised in full by the underwriters on February 21, 2007. Theratechnologies was advised by a team from Fasken Martineau comprised of Robert Girard, Catherine Isabelle, Teri Hoppenheim, and E. Martin Fisher-Haydis for advice on U.S. matters.